• Muhammad Amir Department of Infectious Diseases, Sindh Institute of Urology and Transplantation, Karachi-Pakistan
  • Sunil Department of Infectious Diseases, Sindh Institute of Urology and Transplantation, Karachi-Pakistan
  • Asma Nasim Department of Infectious Diseases, Sindh Institute of Urology and Transplantation, Karachi-Pakistan
  • Zaheer Udin Babar, Department of Infectious Diseases, Sindh Institute of Urology and Transplantation, Karachi-Pakistan




Colistin, Guideline, Pakistan, Resistant


Background: Colistin, also known as Polymyxin E, was the first polymyxin antibiotic. This bactericidal antibiotic plays a vital role as salvage therapy for untreatable gram-negative. Colistin dosing regimens differ worldwide. The published guidelines have different recommendations on the dosing regimens. Further confusion exists due to two different dosing units. Currently, Pakistan has no national guidelines for colistin use. The guideline was developed with the aim of improving the safety profile by developing standardization in colistin use and thus reducing the confusion amongst clinicians. Method: The guideline was developed by a panel of five actively practising infectious disease specialists (physicians and pharmacists) with clinical and research expertise in this particular field. Different literature and international guidelines along with institutional data were used to develop the guideline. Conclusion: The guideline provides ten recommendations on prescribing, transcribing, posology, preparation, administration and monitoring of colistin use. The guideline will give Pakistani healthcare providers a standard approach to using rationally and effectively, and to clear confusion and questions about this medicine.


Syed B, Ishaque S, Imran A, Muslim O, Khalid S, Siddiqui AB. Emergence of colistin-resistant gram-negative rods in intensive care units: A cross-sectional study from a developing country. SAGE Open Med 2022;10:205031212211323.

Ahsan U, Mushtaq F, Saleem S, Malik A, Sarfaraz H, Shahzad M, et al. Emergence of high colistin resistance in carbapenem resistant Acinetobacter baumannii in Pakistan and its potential management through immunomodulatory effect of an extract from Saussurea lappa. Front Pharmacol 2022;13:986802.

Moni M, Sudhir AS, Dipu TS, Mohamed Z, Prabhu BP, Edathadathil F, et al. Clinical efficacy and pharmacokinetics of colistimethate sodium and colistin in critically ill patients in an Indian hospital with high endemic rates of multidrug-resistant Gram-negative bacterial infections: A prospective observational study. Int J Infect Dis 2020;100:497–506.

Labuschagne Q, Schellack N, Gous A, Bronkhorst E, Schellack G, van Tonder L, et al. COLISTIN: adult and paediatric guideline for South Africa, 2016. South Afr J Infect Dis 2016;31(1):3–7.

Association of Scottish Antimicrobial Pharmacists. High Dose Colistimethate Sodium (Colistin) in Adults – Consensus Guidance. Healthcare Improvment Scotland; 2018.

Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 2019;39(1):10–39.

Moolla MS, Whitelaw A, Decloedt EH, Koegelenberg CFN, Parker A. Opportunities to enhance antibiotic stewardship: colistin use and outcomes in a low-resource setting. JAC Antimicrob Resist 2021;3(4):dlab169.

Alotaibi FM, Alshehail BM, Al Jamea ZAH, Joseph R, Alanazi AH, Alhamed NA, et al. Incidence and Risk Factors of Colistin-Induced Nephrotoxicity Associated with The International Consensus Guidelines for the Optimal Use of the Polymyxins: A Retrospective Study in a Tertiary Care Hospital, Saudi Arabia. Antibiotics (Bael) 2022;11(11):1569.

Amir M, Gafoor A, Iqbal Z, Ashraf S, Zeb S. Compassionate Use of Tocilizumab in Patients with Coronavirus Disease 2019 in a Low-resource Country, Pakistan: A Pilot Study. BIO Integr 2021;2(4):180–3.

Babar ZU, Dodani SK, Nasim A. Treatment outcome and adverse effects of colistin in adult patients with carbapenem-resistant gram-negative bacteremia from Pakistan. Int J Infect Dis 2021;106:171–5.

Tran TB, Velkov T, Nation RL, Forrest A, Tsuji BT, Bergen PJ, et al. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet? Int J Antimicrob Agents 2016;48(6):592–7.

Karaiskos I, Friberg LE, Pontikis K, Ioannidis K, Tsagkari V, Galani L, et al. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients. Antimicrob Agents Chemother 2015;59(12):7240–8.

Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, et al. Application of a Loading Dose of Colistin Methanesulfonate in Critically Ill Patients: Population Pharmacokinetics, Protein Binding, and Prediction of Bacterial Kill. Antimicrob Agents Chemother 2012;56(8):4241–9.

Katip W, Uitrakul S, Oberdorfer P. Clinical outcomes and nephrotoxicity of colistin loading dose for treatment of extensively drug-resistant Acinetobacter baumannii in cancer patients. Infect Drug Resist 2017;10:293–8.

Haseeb A, Faidah HS, Alghamdi S, Alotaibi AF, Elrggal ME, Mahrous AJ, et al. Dose Optimization of Colistin: A Systematic Review. Antibiotics (Basel) 2021;10(12):1454.

Kristoffersson AN, Rognås V, Brill MJE, Dishon-Benattar Y, Durante-Mangoni E, Daitch V, et al. Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria. Clin Microbiol Infect 2020;26(12):1644–50.

Karande IS, Goff Z, Kewley J, Mehta S, Snelling T. Dose-Banding of Intravenous Piperacillin-Tazobactam in Pediatric Surgical Inpatients. J Pediatr Pharmacol Ther 2017;22(5):364–8.

Michalopoulos AS, Falagas ME. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care 2011;1(1):30.

Fan Y, Li Y, Chen Y, Yu J, Liu X, Li W, et al. Pharmacokinetics and Pharmacodynamics of Colistin Methanesulfonate in Healthy Chinese Subjects after Multi-Dose Regimen. Antibiotics 2022;11(6):798.

Grégoire N, Mimoz O, Mégarbane B, Comets E, Chatelier D, Lasocki S, et al. New Colistin Population Pharmacokinetic Data in Critically Ill Patients Suggesting an Alternative Loading Dose Rationale. Antimicrob Agents Chemother 2014;58(12):7324–30.

Pai MP. Drug Dosing Based on Weight and Body Surface Area: Mathematical Assumptions and Limitations in Obese Adults. Pharmacotherapy 2012;32(9):856–68.

Falagas ME, Kasiakou SK, Saravolatz LD. Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-Negative Bacterial Infections. Clin Infect Dis 2005;40(9):1333–41.

Hawkey PM, Warren RE, Livermore DM, McNulty CAM, Enoch DA, Otter JA, et al. Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party†. J Antimicrob Chemother 2018;73(Suppl_3):iii2–78.

Arrayasillapatorn N, Promsen P, Kritmetapak K, Anunnatsiri S, Chotmongkol W, Anutrakulchai S. Colistin-Induced Acute Kidney Injury and the Effect on Survival in Patients with Multidrug-Resistant Gram-Negative Infections: Significance of Drug Doses Adjusted to Ideal Body Weight. Int J Nephrol 2021;2021:7795096.

Samarkos M, Papanikolaou K, Sourdi A, Paisios N, Mainas E, Paramythiotou E, et al. The Effect of Different Colistin Dosing Regimens on Nephrotoxicity: A Cohort Study. Antibiotics (Basel) 2022;11(8):1066.

Additional Files